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Abstract:  
Traditional Indian (Ayurvedic) and Chinese herbal medicines have been used in the treatment of a 
variety of diseases for thousands of years because of their natural origin and lesser side effects. However, the 
safety and efficacy data (including dose and quality parameters) on most of these traditional medicines are 
far from sufficient to meet the criteria needed to support their world-wide therapeutic use. Also, the mechanistic 
understanding of most of these herbal medicines is still lacking due to their complex components which further 
limits their wider application and acceptance. Metabolomics -a novel approach to reveal altered metabolism 
(biochemical effects) produced in response to a disease or its therapeutic intervention- has huge potential to 
assess the pharmacology and toxicology of traditional herbal medicines (THMs). Therefore, it is gradually 
becoming a mutually complementary technique to genomics, transcriptomics and proteomics for therapeutic 
evaluation of pharmaceutical products (including THMs); the approach is so called pharmaco-metabolomics. The 
whole paradigm is based on its ability to provide metabolic signatures to confirm the diseased condition and 
then to use the concentration profiles of these biomarkers to assess the therapeutic response. Nuclear magnetic 
resonance (NMR) spectroscopy coupled with multivariate data analysis is currently the method of choice for 
pharmaco-metabolomics studies owing to its unbiased, non-destructive nature and minimal sample preparation 
requirement. In recent past, dozens of NMR based pharmaco-metabolomic studies have been devoted to prove 
the therapeutic efficacy/safety and to explore the underlying mechanisms of THMs, with promising results. The 
current perspective article summarizes various such studies in addition to describing the technical and 
conceptual aspects involved in NMR based pharmaco-metabolomics.  
  
Introduction: 
Metabolomics -a newborn cousin to genomics and proteomics- is an analytical approach to metabolism that 
involves quantitative and comparative analysis of concentration profiles of low molecular weight metabolites 
and their intermediates in affected biological systems (typically urine, blood-plasma/serum, cell lysates, or 
tissue extracts). Genomics, transcriptomics and proteomics analysis complemented with metabolomics 
information, offers the potential to understand the whole biological system including health or disease 
processes operating in that system –so called systems biology approach (Fig. 1). With its ability to discover 
disease related biomarkers and underlying biochemical processes, today, metabolomics is used virtually in all 
aspects of biomedical research aiming to improve the understanding of the health and disease processes. The 
whole paradigm is based on the fact that a pathophysiological condition or therapeutic intervention results in a 
specific and characteristic change in the biochemical composition profiles of biofluids and metabolomics aims to 
identify these changes. The biochemical changes -that correlate to a disease (or disease type/grade) and/or 
treatment response- then allow the clinical researchers to improve diagnosis and treatment of disease including, 
early disease detection, monitoring response to treatment and patient stratification for treatment. The 
molecular biomarkers validated on wide-range of human populations form the basis for new clinical diagnostic 
assays. 
 
Figure 1: Schematic showing (on left) technological platforms of systems biology approach: genomics, transcriptomics, 
proteomics, and metabolomics and (on right) generalized mode of action of traditional herbal medicines (THMs). Overall, 
it highlights the fact that the active components of THMs can interact with various cellular components (i.e. DNA, RNA, and 
proteins) to exert combined synergistic therapeutic effect.  
Metabolomics is also gaining tremendous popularity in pharmaceutical research owing to close 
technical and conceptual overlap between the two[1]. In particular, because of its ability to reveal altered 
metabolism in response to a therapeutic intervention, it is now routinely used in pharmaceutical research[2] 
particularly meant for (a) understanding the underlying mechanisms of drug action, (b) studying the biochemical 
effects produced in response to a drug treatment and (c) assuring the quality, safety and efficacy of 
pharmaceutical products. Such an explosion of metabolomics applications in various important areas of 
pharmaceutical research has led to origin of new discipline called Pharmaco-metabolomics[3,4] which particularly 
aims to improve the efficacy and reduce the side effects associated with a treatment. Pharmaco-metabolomics 
is also widely used as complementary tool in understanding biological changes after a drug intervention or a 
gene knockout[5]. Recently, it is gaining tremendous popularity in ethano-pharmacological studies aiming to 
evaluate the efficacy and safety of traditional herbal medicines (THMs) [1,3-6].   
Table 1: Summarized 1H NMR based pharmacometabolomics studies carried out to investigate the 
pharmacological outcome of traditional herbal medicines: 
# Traditional Herbal 
Medicine 
Evaluated drug effect on rat/mouse models Ref 
1 Curcumin1 Evaluated anti-Hyperlipidemic properties  Li Z Y et. al.[7] 
2 Sini decoction2 Evaluated therapeutic efficay against myocardial 
infarction 
Tan G et. al. [8] 
3 Coptidis Rhizome2 Evaluated drug-induced gastrointestinal reaction Zhou Y et. al.[9] 
4 Niuhuang Jiedu Tablet 
(NJT)2 
Evaluated its As2S2 toxicity alleviation effect Xu W et. al.[10] 
5 Herba Rhodiolae2 Evaluated its Anti-hypoxia and anti-anxiety effects  Liu X et. al.[11] 
6 Astragali Radix 
(Huangqi)2 
Evaluated its anti-fatigue effect Li Z Y et. al.[12] 
7 Danggui (DG)2 Evaluated and compared the drug efficacy of 
Chinese and European variants of Danggui 
Zhang Z Z 
et.al.l[13] 
8 Xiaoyaosan2 Evaluated its therapeutic response in depressed 
patients 
Liu C C et. al. [14] 
9 Astragali Radix2 Compared the clinical efficacy and safety of two 
different forms of Astragali Radix 
Li A P et. al. [15] 
10 Qin-Re-Jie-Du (QRJD) and 
Liang-Xue-Huo-Xue 
(LXHX)2 
Evaluated differential efficacy of these traditional 
formulations in septic rats. 
Li Y  et. al.[16] 
11 Curcuma aromatica oil1 Evaluated its intervening effects on renal interstitial 
fibrosis rats 
Zhao L et. al.[17,18] 
12 Centella asiatica1 Evaluated its in vivo antidiabetic property on obese 
diabetes rats 
Abas F et. al.[19] 
13 Total Alkaloid of 
Corydalis Rhizoma2 
Evaluated its therapeutic efficacy against 
depression on chronic unpredictable mild stress rat 
model 
Hongwei W et. 
al.[20] 
1Traditional Herbal Medicine; 2Chinese Herbal Medicine;  
 
The most information-rich techniques currently employed in metabolomics studies are mass spectrometry (MS) 
and nuclear magnetic resonance (NMR) spectroscopy. Among these two techniques, MS is highly sensitive, with 
detection limits in the picogram range, however, for MS-based metabolomics studies, it requires a separation 
step (liquid chromatography/gas chromatography) before the MS detection. This requirement dictates that 
each sample will requires hours per MS analysis. The overall throughput is further hampered by many unsolved 
problems such as (a) non-uniform detection caused by variable ionization efficiency, (b) lack of well-established 
and standardized methods or procedures (as it requires optimization of separation conditions each time), and 
(c) the difficulties still met in the identification of novel/unknown metabolites produced in response to a given 
therapeutic intervention. Although less sensitive (with detection limits in the low micromolar to sub-micromolar 
range) than MS, NMR is generally appreciated for metabolic analysis because of its versatility for analyzing 
metabolites in the liquid state (serum, urine, and so on), in intact tissues (for example, tumors) or in vivo (e.g. 
brain, liver, kidney, and so on). The powerful strengths of NMR spectroscopy are reproducibility, the ability to 
quantitate compounds in unmodified complex biological mixtures and the ability to identify unknown 
metabolites[21-23]. In recent past, the dozens of NMR based pharmaco-metabolomic studies have been carried 
out to prove the therapeutic efficacy/safety and to explore the underlying mechanisms of THMs, with promising 
results. Table 1 summarizes some of these reports where the 1H NMR-based metabonomics approach has been 
used to investigate the pharmacological outcomes with traditional herbal medicines. The metabolomics 
approach has also been employed for studying the adverse toxic effects on experimental models (in terms of 
perturbed biochemical composition profiles) in response to traditional herbal medicines)[24,25].  
 
Technological Advantages of NMR: 
Compared to other analytical and biochemical analysis methods used for metabolomics studies, NMR offers 
several clear advantages[26]: (a) first, it is applicable for a variety of biological and clinical samples, tissue 
extracts and even cell lysates, (b) second, it is rapid, quantitative, and offers the potential for high-throughput 
(i.e. analysis of >100 samples/day is attainable), (c) third, it is least-destructive (i.e. the prepared sample can 
be used in multiple consecutive NMR experiments, or after the NMR experiments are completed, the sample 
can be analyzed by other analytical techniques), (d) fourth, it is un-biased (i.e. all protonated metabolites 
present in a biological mixture are detectable irrespective of their physical properties) and (e) last but not the 
least, it requires virtually no sample preparation and provides highly reproducible results. These are the 
reasons that NMR has become the method of choice for studying metabolic alterations associated with distinct 
human pathologies and also gaining tremendous popularity in pharmaco-metabolomics studies as well[27]. 
Today, the sensitivity of NMR is also not a major issue; even low nanogram detection limits are possible with 
appropriate instrumentation and novel pulse methodology[28]. Further, the recent technological advances in 
cryogenically cooled probe technology, the miniaturizing of sample probe head (i.e. with microvolume probe it 
is now possible to analyze samples in 10 μl solution), higher field-strength superconducting magnets and high-
performance radiofrequency coils have increased the sensitivity of NMR spectrometers by a factor of ~ 3–
4[29,30]. 
General Guidelines for NMR based Pharmaco-metabolomics: 
A typical NMR based pharmaco-metabolomics study employed to evaluate the therapeutic efficacy 
and safety of THMs is performed in two steps: (a) first step involves the identification of the disease specific 
biomarkers –referred here as disease metabotyping (Fig. 2) and (b) second step involves the use of these 
biomarkers to assess the therapeutic efficacy. The various technical and conceptual aspects related to both 
these steps are described further.  
(A) Disease metabotyping: 
Disease metabotyping involves identification of disease specific metabolic profiles referred here as metabolic 
signatures or biomarkers. The identified metabolic signatures then allow the drug researchers and drug 
regulators to address many of the riskier or expensive issues associated with the discovery, development and 
monitoring of novel therapeutic candidates through providing early preclinical indications of efficacy and 
toxicity of a potential drug candidate[26]. Figure 2 schemically illustrates the generalized protocol employed in 
NMR based disease metabotyping. Typically, it involves the following steps: 
 
Figure 2: Flowchart depicting generalized protocol for identifying disease-specific metabolic signatures using 
NMR based metabolomics approach.  
(a) Animals experiments  
Typically, the NMR-based pharmaco-metabonomics studies focus on the metabolic profiles of biofluids 
(specifically urine, serum and tissue extracts) obtained from normal and treated experimental animal models. 
As such, these studies involve male rats/mice which are first subjected to acclimatization (at least for seven 
days). Throughout acclimatization and intervention period, the rats/mice are provided with uniform diet and 
tap water ad libitum and are generally kept under ambient temperature of 25 ± 2 °C with 12 hours day and 
night cycle and 40% - 60% relative humidity. After acclimatization, the rats/mice are divided randomly into a 
control group and a few (generally 3-4) intervention groups. For toxicological studies, the normal rats are 
given different doses of the treatment. Whereas for pharmacological studies, all the rats/mice in each group 
are first induced with diseased condition or then given the therapeutic treatment as per the study protocol. At 
the end of treatment period, rats/mice from each group are subjected to ethological evaluation following the 
protocols described previously[31,32]. After ethological evaluation, all experimental rats/mice are sacrificed by 
decapitation and required blood and tissue samples are quickly extracted from each rat/mouse, snap-frozen 
in liquid nitrogen and subsequently stored at -80 °C before NMR analysis. For urinary metabolic profiling, 
urine samples are collected at regular time intervals before and during the intervention period. Generally 
midstream urine is collected (minimum 0.5 ml) and transferred to appropriately labeled tubes, immediately 
cooled or flash-freezed, and stored at -80 °C. For extracting serum samples, the whole blood is collected in a 
plain tube and incubated at room temperature (generally 25 °C) for 30 minutes. As a general rule, 1.0 ml of 
whole blood yields ~0.5 ml of serum which is well sufficient for NMR data collection in conventional 5 mm 
tubes. The resulted supernatant is then transferred to a 1.5 ml microcentrifuge tube (MCT) and centrifuged at 
2,500 rpm for 10 minutes (at room temperature to precipitate the sediments). The resulted supernatant –
referred as serum- is then transferred to appropriately labelled sterile tubes, immediately cooled or flash 
freezed, and stored at -80 °C.  For metabolomics studies, the stored samples are thawed 1-2 hours before 
starting the NMR experiments and prepared following the previously reported NMR sample preparation 
protocols[33,34]. Depending upon the situation in hand or availability of the biofluid, the users may change the 
protocol. Such an optimal protocol for urine and serum sample preparation for NMR based metabolomics 
studies is depicted here schematically in Figure 3. Regarding NMR of tissue samples, it has other specific 
requirements depending upon whether the metabolic profiles of tissue samples are studied (a) directly i.e. using 
high-resolution magic angle spinning (HR-MAS) NMR as described previously[35] or (b) indirectly i.e. tissue 
extracts are prepared [34,36,37] and characterized using standard solution state NMR. It is important to mention 
here is that the NMR chemical shifts are highly sensitive to sample conditions (like sample temperature, pH, ionic 
strength, etc.), therefore, while collecting urine/blood, it is important to treat all of the samples the same way to 
avoid inter-spectral variation of chemical shifts. Though, urine samples contain minimal fat and protein content 
and therefore owing to its non-viscous nature, the NMR spectra of urine (Figure 4A) show the highest sensitivity 
and resolution. However, inter-spectral variations are common particularly in case of urine samples. This is 
because, the biochemical composition profiles of urine are influenced by a range of different factors e.g. diet, 
time of food intake, amount of water consumption, seasonal variations, gender of the subject (male/female) or 
physical activity prior to sample collection[38]. Further, collecting urine samples from animal models is an 
arduous job and requires utmost precaution to avoid contamination. On the other hand, the biochemical 
composition profiles in sera extracted from blood collected after overnight fasting are less sensitive for such 
variations rendering serum samples quite apposite for routine metabolomics studies. 
 
Figure 3: Flowchart showing generalized protocol for preparing the urine and serum samples for NMR based 
metabolomics studies. The protocol assumes that in each case, more than 300 l of serum and more than 540 l of urine is 
obtained. 
 
(b) NMR experiments: 
One-dimensional (1D) 1H NMR is widely used technique for quantitative proilfing of complex metabolite 
mixtures of bio-fluids (like urine and serum) and average time spent for sample preparation and NMR data 
collection is generally 10-15 minutes. Routinely, after data collection, the metabolite signals observed in the 1H 
NMR spectra of serum/urine are assigned (as depicted in Figure 4B) by comparison with spectra of standard 
compounds (www.bml-nmr.org) or performing metabolite spiking with standrad authentic compounds[39]. 
Additional 2-dimensional NMR experiments (including J-resolved, 1H-1H TOCSY and heteronuclear 1H-13C 
HSQC correlation experiments) are performed for the purpose of confirming chemical shift assignments using 
software programs like Metabominer[40,41]. In addition, the metabolite peaks can be assigned making use of 
chemical shift databases (www.hmdb.ca), previosuly reported chemical shifts in the literature, and software 
tools like CHENOMX (Edomonton, Canada))[39,41].  
 
Figure 4: (A) Stack plot of representative 800 MHz one-dimensional 1H CPMG (Carr-Purcell-Meiboom-Gill) NMR spectra 
of rat urine (in red) and rat serum (in blue) recorded using cpmgpr1d pulse sequence from Bruker library with water 
presaturation during recycle delay of 5 sec and T2 filter time of 60 ms (for suppressing the singals of higher MW proteins 
and fats). Unlike urine, the 1D 1H NMR spectrum of serum is relatively simple and less crowded as evident in (B). The 
lables in (B) represent the metabolite specific assignment of peaks using in CHENOMX profiler. 
(c) Statistical Analysis:  
Following NMR data collection and spectral assignment, the next step is to identify the distinct metabolic 
patterns or disturbances associated with the diseased state. Owing to spectral complexity, various data 
refinement and multivariate statistical analysis tools are used to extract the relevant information[42]. First, the 
acquired series of NMR spectra are processed (including phase and baseline correction) and calibrated 
generally with respect to an internal reference (typically lactate in case of serum and creatinine in case of 
urine).  Next, the spectral data is transformed into a data matrix following various data pre-processing and 
refinment steps: (a) binning i.e. each spectrum is divided into equally sized (typically 0.01-0.04 ppm)  bins (Fig. 
5a), so that integral (area) of each bin represents a new point in the binned spectrum, (b) normalization where 
each spectrum is normalized such that its integral is 1 (this is so called internal scaling and is used to account for 
variable dilution factors of biological samples), and (c) centering and scaling (a table column operation; is used 
to reduce the influence of intense peaks while emphasizing weaker peaks)[43-45]. The software tools available to 
perform various such operations include AMIX (Bruker Biospin), CHENOMX NMR suite (www.chenomx.com) and 
Mnova NMR (http://mestrelab.com).  
After binning, normalization and scaling, the resulted data matrix is subjected to multivariate statistical analysis 
simulatenously to reduce the dimensionality of the data and recognizing the trends/patterns[46-52]. Typically, it 
includes two steps: unsupervised and/or supervised analysis. Unsupervised analysis aims at finding intrinsic 
variation within a group (i.e. grouping trend) and patterns in the data using methods such as hierarchical 
clustering analysis (HCA, often used to assess, how similar or different the diseased sample groups are 
compared to normal control samples)[50,52] and principal component analysis (PCA, a data reduction technique 
used to reduce the dimensionality of a multi-dimensional dataset while retaining the characteristics of the 
dataset that contribute most to its variance)[45,46,53].  
  
Figure 5: (a) Representative arrayed NMR dataset recroded on rat serum samples (related to an ongoing pharmaco-
metabolomics study in the lab) with vertical grey lines highlighting the data binning (or so called bucketing). (b) An 
illustrattive PLS-DA score plot (with semi-transparent confidence intervals) derived from NMR based serum metabolic 
profiles of control and diseased groups. (c) A representative box-cum-whisker plot of a example discriminatory metabolite 
(i.e. putative biomarker) elevated in diseased state. Horizontal line inside the box is the median and bottom and top 
boundaries of boxes are 25th and 75th percentiles, respectively. Lower and upper whiskers are 5th and 95th percentiles, 
respectively, and (d) corresponding ROC (Receiver operating characteristic) curve plot based on the serum levels observed 
in control and diseased state highlighting the diagnostic potential of the biomarker.  
 
Supervised analysis, on the other hand, allows for statistical inference regarding features and groups to assess 
the clustering behavior between groups. The most common statistical model applied for supervised analysis is 
Partial Least Squares for Discriminant Analysis (PLS-DA) which is a regression extension of PCA and takes 
advantage of class information to attempt to maximize the separation between groups of observations. The 
PLS-DA analysis also helps to identify the marker metabolites that can differentiate the two groups. These 
metabolites are further verfied using univariate analysis including student t-test, ROC (Receiver operating 
characteristic) curve analysis (Fig. 5b-d).  However, supervised analysis based on PLS-DA model often tends to 
over fit the data and therefore the model needs to be rigorously validated to see whether the separation is 
statistically significant or is due to random noise[54]. The commonly used software tools for multivariate data 
analysis include MUMA-R_Package[55], MVAPACK[56], Unscrambler (CAMO USA, Norway: www.camo.com), 
SIMCA (Soft Independent modeling by Class Analogy: umetrics.com/products/simca), Metaboanalyst 
(http://www.metaboanalyst.ca)[50,52], etc. Important to mention here is that the Metaboanalyst is a free web-
based server which allows comprehensive metabolomic data analysis, visualization and validation [52]. The 
example PLS-DA score plot shown in Figure 5b  has been generated using Metaboanalyst server. In addition, 
metaboanalyst also perfoms model validation (R-squared analysis), helps to evaluate model quality (Q-
squared analysis) and does allow the univariate analysis (including box plot data visualization and ROC curve 
analysis). The box plot (showing difference in the concentration profiles of a discriminatory metabolite 
identified based on  PLS-DA model) and the corresponding ROC-curve shown in Figure 5d and 5e have also 
been generated using Metaboanalyst server. On top of all this, the other strength of metaboanalyst is that it 
further allows integrative pathway analysis of genes and metabolites for biologically relevant interpretion of 
observed biochemical changes (as depicted in Figure 6); thus helps to validate and generate disease 
hypothesis for scientific acceptance[52]. Overall, the NMR spectroscopy coupled with multivariate statistical 
analysis allows the identification of metabolic disturbances and/or specific metabolic pathways associated with 
the disease, but it also allows the identification of metabolic signatures which have their potential diagnostic 
and prognostic implications for clinical management of the disease. 
(B) Assessing Therapeutic efficacy and safety of traditional Herbal Medicines (THMs) using 
metabolomics analysis 
Therapeutic evaluation of herbal drugs is one of the essential steps employed for demonstrating their utility in 
clinical practice. However unlike a conventional medicine, a herbal formula based on a THM is composed of 
complicated chemical components which work as a holistic system for curing the disease. Biologically, a THM 
produces the therapeutic effect synergistically affecting multiple cellular targets. Therefore, for in-depth 
understanding of underlying efficacies and mechanisms of action for such holistic herbal recipes, the systems 
biology has been recognized as a novel approach[57-59]. Its technological platforms, such as genomics, 
transcriptomics, proteomics and metabolomics, together provide in-depth understanding of whole range of 
biological and biochemical effects (including molecular interactions, molecular pathways and regulatory 
networks) (Figure 1). The systems biology approach is also gaining tremendous popularity for assessing the 
pharmacological and toxicological effects of herbal recipes. 
 Figure 6: Summary of metabolic pathways enrichment analysis performed in MetaboAnalyst (Version 3.0, URL: 
http://www.metaboanalyst.ca) using a set of 21 metabolites found to be significantly altered in AMI patients compared 
to normal controls (in a preliminary study from our lab). The used metabolite entities were: Isoleucine, Leucine, Valine, 
Alanine, Acetate, Glutamate, Glutamine, Citrate, TMAO, Glucose, Glycine, Glycerol, Creatine, Creatinine, Serine, 
Histidine, Phenylalanine, Lactate, Proline, Threonine, and Choline. The most significant p-values are in red while the least 
significant are in yellow and white. Pathway analysis showing altered metabolic pathways. 
 
Metabonomics is a top-down systems biology approach (Figure 1) and plays a key role in the convergence of 
systems biology studies. Today, it is also extensively used in basic and applied research for assessing the 
pharmaceutical efficacy and toxicity.  The 1H NMR spectroscopy coupled with multivariate data analysis is 
currently the technique of choice for metabolomics studies meant for studying the biochemical composition 
profiles and metabolic pathway perturbations from urine and blood samples. Figure 7 schemically illustartes 
the generalized protocol employed in NMR based pharamcometabolomics studies and Figure 8 schemically 
shows the metabolic reprogramming after therapeutic intervention (in dose dependent manner). Additionally, 
the data collected for evaluating the therapeutic efficacy of the drug can be used to widen the understanding 
of metabolic pathways implicated in response to drug treatment and therefore can help unravel the underlying 
mechanism of drug action (Fig. 5). Additional health related issues associated with THMs include the quality 
control of the production and optimum dosage. Metabolomics, however, can also be applied for the assessment 
of quality control of herbal medicines and finding optimum non-toxic dose of such THMs as elegantly described 
previously[58-62]. 
 Figure 7: Flowchart depicting generalized protocol for evaluating the in vivo efficacy and safety of new 
therapeutic formulation using metabolomics approach.  
Concluding Remarks: 
Pharmaco-metabolomics is a rapidly emerging discipline in biomedical research pertaining to human-
healthcare and providing a new perspective for studying the outcome of a treatment including herbal 
medicines. The central to pharmaco-metabolomics is to characterize the metabolic-perturbations/metabolic-
pathways implicated in response to a therapeutic intervention. It further offers a useful tool to identify disease 
biomarkers and therefore provides a novel methodological cue for systematically dissecting the underlying 
mechanisms of drug action and biochemical effects produced in response to drug treatment. In this report, we 
have highlighted the potential of NMR for screening pharmacological outcomes. The particular advantage of 
the approach is its rapidity and reproduciblity with little or no added technical resources to existing in vivo 
studies. New technological and methodological advances in combination with  rapid generation of metabolomic 
databases and automated algorithms for data processing and analysis has significantly improved the 
qualitative and quantitative power of this approach rendering it a useful tool in pharmaceutical research and 
development including mechanistic exploration. A future challenge, however, is to validate the pharamco-
metabolomics findings in large and prospective, well-controlled clinical studies involing demographically 
diverse human patient populations. Nevertheless, the approach holds a great promise to widen the 
understanding of underlying efficacies and mechanisms of action. 
 
Figure 8: Schematic PLS-DA score plots depicting metabolic reprogramming duing treatment (A) or after 
treatment in a dose dependent manner (B). (C) box plot of a metabolite elevated in diseased state and 
resetting back to its normal level after treatment. 
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